Healthcare
Carlyle hires ex-Johnson & Johnson chair to advise Asia buyout
The Carlyle Group has hired Jesse Wu, the former chairman of Johnson & Johnson China, as a senior advisor to the firm’s Asia buyout team.
OrbiMed, Chinese strategic to buy Canadian healthcare player
OrbiMed will consolidate its control of Canada-listed clinical equipment producer Response Biomedical in an C$11.1 million ($8.6 million) take-private deal including participation by Shanghai Runda Medical Technology.
HighLight Capital leads $7.6m round for TCM play
Chinese healthcare-focused GP HighLight Capital has led a RMB50 million ($7.6 million) Series B round for Jun He Tang, a traditional Chinese medicine (TCM) business, followed by existing investor Qiming Venture Partners.
Shenzhen Hepalink commits $60m to TPG biotech fund
Chinese drug maker Shenzhen Hepalink Pharmaceutical has agreed to commit $60 million to TPG Capital’s latest biotech fund.
India's Lok Capital reaches $40m first close on third fund
Indian venture capital firm Lok Capital has reached a first close of $40.5 million for its third fund, which is targeting a $100 million total corpus within 12-18 months.
IFC to anchor $200m round for India's Glenmark
The International Finance Corporation (IFC), the investment arm of the World Bank, will anchor a planned $200 million funding round for India's Glenmark Pharmaceuticals, committing up to $75 million.
IBM launches Asia-focused tech accelerator in Singapore
IBM has launched an accelerator in Singapore that will help Asia Pacific start-ups commercialize blockchain technology and the cognitive computing system known as Watson.
Japan's middle market: Simmering prosperity
GPs are finding opportunity in Japan’s economic stagnancy and dramatic demographic trends, but embracing this massive market will require a sharper focus on planning, as well as patience and poise
Australia's Starfish in $17.5m China push for US marketing company
Australian VC firm Starfish Ventures has joined a $17.5 million round for Aktana, a US and Japan-based marketing services provider looking to consolidate its Asian footprint.
IKang chairman, Meinian withdraw take-private bids
Ligang Zhang, founder and CEO of US-listed Chinese company iKang Healthcare Group, and a consortium led by Meinian Onehealth Healthcare Group, have withdrawn their privatization proposals for iKang after the company received a new offer from Yunfeng Capital.
Yunfeng joins the battle for US-listed iKang
Chinese healthcare services provider iKang Healthcare Group, which became the take-private target of a string of PE and strategic investors, has received a new competing bid from Yunfeng Capital.
Warburg Pincus to make partial exit from China Biologic
Warburg Pincus has agreed to make another partial exit from China Biologic Products, a US-listed bio-pharmaceutical developer, generating proceeds of about $308 million.
Japan’s Whill closes $17.5m Series B
Eight Roads Ventures has led a $17.5 million Series B round for Japanese wheelchair and personal mobility device developer Whill.
Lilly Asia, SBCVC invest $15m in China online drug seller
Healthcare-focused GP Lilly Asia Ventures and SBCVC have participated in a RMB100 million ($15 million) Series A round for 360 Haoyao, an online drug seller established by Chinese software company Qihoo360 Technology.
Vivo raises $100m for Sino-US healthcare VC fund
Healthcare specialist Vivo Capital has closed its latest Sino-US venture capital fund with around $100 million in commitments. The vehicle will focus on early-stage investments.
IFC to invest $68m in India's Apollo Health
The International Finance Corporation (IFC), the investment arm of the World Bank, has committed $68 million to Indian clinic chain Apollo Health and Lifestyle (AHL).
Healthcare app launched by China's Ping An Insurance raises $500m
Ping An Good Doctor, a healthcare-focused mobile app controlled by Chinese Ping An Insurance Group, has raised $500 million in a Series A round of funding at a valuation of $3 billion.
WI Harper raises $175m Asia fund
WI Harper Group has closed its eighth venture capital fund, which targets early-stage investments in Asia-focused companies, at $175 million.
Fosun Pharma makes offer for India's KKR-backed Gland
Hong Kong-listed drug maker Fosun Pharmaceutical has made a non-binding proposal to acquire Gland Pharma, an Indian pharmaceutical developer backed by KKR.
China Everbright acquires elderly care business
China Everbright has acquired a 67.3% stake in Beijing Huichen Nursing Home Management, a healthcare services provider for more than 10,000 Chinese seniors.
Tower Capital, Temasek bid $196m for China TCM player
Tower Capital, a vehicle controlled by former 3i and Actis Capital Partners executive Danny Koh, is partnering with Temasek Holdings in a S$269 million ($196 million) takeover bid for traditional Chinese medicine (TCM) operator Eu Yan Sang International.
CDH makes partial exit from Hong Kong-listed Luye Pharma
CDH Investments has made another partial exit from China-based drug developer Luye Pharma, generating proceeds of between HK$709 million ($91.4 million) and HK$729 million.
Japanese pharma group launches global VC arm
Japanese oncology specialist Taiho Pharmaceutical has launched a VC arm that will invest an initial pool of $50 million in global start-ups focused on cancer therapies.
China TCM clinic chain Gu Sheng Tang raises $70m
Gu Sheng Tang, a traditional Chinese medicine (TCM) clinic chain, has raised $70 million in a Series C round led by US-based insurance firm Starr Companies, followed by China Ping An Insurance.